Hematopoietic and Lymphoid System Neoplasm Withdrawn Phase 2 Trials for Cyclophosphamide (DB00531)

Back to Hematopoietic and Lymphoid System Neoplasm
IndicationStatusPhase
DBCOND0132171 (Hematopoietic and Lymphoid System Neoplasm)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03602898Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationTreatment